Kinnate Biopharma Future Growth

Future criteria checks 0/6

Kinnate Biopharma is forecast to grow earnings and revenue by 14.6% and 69.1% per annum respectively while EPS is expected to grow by 33.6% per annum.

Key information

14.6%

Earnings growth rate

33.6%

EPS growth rate

Biotechs earnings growth	24.8%
Revenue growth rate	69.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	03 Apr 2024

Recent future growth updates

Recent updates

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Sep 15

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Aug 11

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

May 15

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Jan 24

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Oct 09

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Jun 22

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Mar 03

Kinnate Biopharma earns bulls as IPO quiet period ends

Dec 28

Earnings and Revenue Growth Forecasts

NasdaqGS:KNTE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-69	-36	-23	2
12/31/2025	N/A	-53	-37	-37	3
12/31/2024	N/A	-59	-54	-54	4
12/31/2023	N/A	-113	-100	-100	N/A
9/30/2023	N/A	-127	-107	-106	N/A
6/30/2023	N/A	-127	-102	-102	N/A
3/31/2023	N/A	-122	-96	-96	N/A
12/31/2022	N/A	-116	-92	-89	N/A
9/30/2022	N/A	-111	-91	-88	N/A
6/30/2022	N/A	-105	-88	-85	N/A
3/31/2022	N/A	-99	-81	-79	N/A
12/31/2021	N/A	-90	-72	-71	N/A
9/30/2021	N/A	-77	-62	-62	N/A
6/30/2021	N/A	-63	-53	-53	N/A
3/31/2021	N/A	-49	-41	-41	N/A
12/31/2020	N/A	-36	-30	-30	N/A
9/30/2020	N/A	-26	-20	-20	N/A
12/31/2019	N/A	-10	-11	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KNTE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KNTE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KNTE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KNTE is forecast to have no revenue next year.

High Growth Revenue: KNTE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KNTE's Return on Equity is forecast to be high in 3 years time

Kinnate Biopharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 21% to US$4.53

Price target decreased by 84% to US$3.75

Price target increased by 8.1% to US$25.86

Price target decreased by 16% to US$25.00

Price target decreased to US$31.88

Price target decreased to US$40.71

Recent updates

Kinnate Biopharma Files Form 15

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index

Price target increased by 21% to US$4.53

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Price target decreased by 84% to US$3.75

Insufficient new directors

Kinnate Biopharma Inc. Announces Workforce Restructuring

New minor risk - Market cap size

Price target increased by 8.1% to US$25.86

Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

Price target decreased by 16% to US$25.00

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Kinnate Biopharma Inc. Appoints Jill DeSimone as Independent Director, Effective on March 1, 2023

Kinnate Biopharma Inc. to Present Trials in Progress Poster for Its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Price target decreased to US$31.88

High number of new and inexperienced directors

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Kinnate Biopharma Inc. Announces Pipeline Update

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from Russell 2000 Growth Index

Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

Price target decreased to US$40.71

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

High number of new and inexperienced directors

Kinnate Biopharma Inc., Annual General Meeting, Jun 10, 2022

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Its FGFR Inhibitor Product Candidate, KIN-3248

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

Price target decreased to US$43.43

Chief Medical Officer recently bought US$339k worth of stock

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation At the American Association for Cancer Research Annual Meeting

Kinnate Biopharma Inc. to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Kinnate Biopharma Inc. Announces U.S Food and Drug Administration Clearance of Investigational Drug Application for KIN-3248

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Kinnate Biopharma Inc. Announces That the First Patient Has Commenced Treatment in its Phase 1 KN-8701 Clinical Trial

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Director Stephen Kaldor has left the company

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

New 90-day low: US$29.70

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Kinnate Biopharma earns bulls as IPO quiet period ends

Kinnate Biopharma Inc. has completed an IPO in the amount of $240 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies